Archive for February, 2012

Genetics of endangered African monkey suggest troubles from warming climate

February 29th, 2012

ScienceDaily (Feb. 29, 2012) A rare and endangered monkey in an African equatorial rainforest is providing a look into our climatic future through its DNA. Its genes show that wild drills (Mandrillus leucophaeus), already an overhunted species, may see a dramatic population decline if the forest dries out and vegetation becomes sparser amid warming temperatures, researchers report.

Looking for clues amid 2,076 base pairs of mitochondrial DNA — genes passed down along female lineages — researchers discovered genetic signs that coincide with the conditions that mirror current climate projections for the equator around the globe in the next 100 years. Also examined were the region’s fossil and pollen records.

“The drills went through a large population collapse — as much as 15-fold,” said Nelson Ting, a professor of anthropology at the University of Oregon. Ting is the lead author of a study placed online ahead of regular publication in the journal Ecology and Evolution. “This occurred sometime around the mid-Holocene, which was about 3,000 to 5,000 years ago.”

Ting and 10 other researchers — representing institutions in the United States, United Kingdom, Nigeria and Germany — gathered feces of drills in the Cross-Sanaga-Bioko Coastal forests that stretch across portions of Nigeria, Bioko Island (Equatorial Guinea) and Cameroon. The extracted DNA provided the first genetic information from this species, which is found only in that region.

The species also is struggling for survival because of poaching and by habitat loss due to logging and cultivation activities. Drill meat also is a valued food; hunters often shoot them en masse. Protecting drill populations was the top priority of the African Primate Conservation Action Plan developed in 1996 by the International Union for Conservation of Nature. Despite the designation, Ting said, “hunting continues and is the much more immediate danger facing the drill.”

The base pairs examined came from 54 samples of DNA. Base pairs are made up of adenine, thymine, guanine and cytosine. While DNA is the blueprint for life, examining the sequences of these chemicals also provides a roadmap into any organism’s past. “Looking at its modern genetic diversity, you can infer changes in past population size,” Ting said.

In the mid-Holocene, temperatures across equatorial Africa were hotter and dryer, with a reduction of forest cover that the drill need for survival. The ecology of the region also includes multiple other species found only there. The research, Ting said, is among emerging work focusing on past climate conditions in equatorial areas. Many studies have been done on conditions in both temperate and arctic regions.

The findings carry conservation implications, Ting said. “We could see many of these equatorial forests becoming very arid. Forest will be lost as vegetation changes to adapt to dryer conditions. Our findings show that this type of animal, which already is very much endangered because of hunters, would not be able to deal with the level of climate changes that could be coming.”

What is needed to protect this little understood species are measures that reduce the destruction of the forest habitat and step up protection against poachers, said Ting, who is co-director of the UO’s molecular anthropology group and a member of the UO Institute of Ecology and Evolution and UO Institute of Cognitive and Decision Sciences.

The other co-authors on the paper were Christos Astaras of the University of Oxford, United Kingdom; Gail Hearn and Shaya Honarvar of Drexel University in Philadelphia; Joel Corush, a research assistant in the UO molecular anthropology group; Andrew S. Burrell of New York University; Naomi Phillips of Arcadia University in Glenside, Pa.; Bethan J. Morgan of the University of Stirling, United Kingdom, and member of CERCOPAN, a non-profit, non-government organizations working for conservation in Nigeria; Elizabeth L. Gadsby of the San Diego Zoo Global Institute for Conservation Research; Ryan Raaum of Lehman College and City University of New York Graduate Center, West Bronx, N.Y.; and Christian Roos of the Gene Bank of Primates and Primate Genetics Laboratory, German Primate Center, Gottingen, Germany.

Read this article:
Genetics of endangered African monkey suggest troubles from warming climate

Natural Molecular Testing Corp. (NMTC) Names Karthikeshwar Kasirajan, M.D., as Chief Medical Officer

February 29th, 2012

SEATTLE–(BUSINESS WIRE)–

Natural Molecular Testing Corp. (NMTC), a company providing groundbreaking clinical molecular testing and services in the medical genomics field, today announced that Karthikeshwar Kasirajan, M.D., has joined the company as Chief Medical Officer. Dr. Kasirajan will oversee the companys efforts to develop adverse drug interaction tools and disease registries, and expand NMTCs outreach to physicians and clinical partners.

NMTC, a privately-owned company, provides accurate and high-speed genetic testing to identify a patients specific phenotypes. The test results offer physicians guidance in prescribing and dosing medication for more safe and effective treatment.

Clinical molecular testing is playing an increasingly important role in better serving patients, and NMTCs cutting-edge laboratory provides physicians with important genetics data, said Dr. Kasirajan. Im excited to support the companys focus on optimizing patient outcomes, cost-efficiencies for physicians, and lowering health-care costs through the use of genetic testing.

NMTC Chief Executive Officer Beau R. Fessenden said Dr. Kasirajans addition to the companys executive team accelerates several NMTCs initiatives.

Physicians knowledge of genomics varies widely and new advances are constant, said Fessenden. Dr. Kasirajan brings a doctors perspective to the real-world need for improved diagnostics by identifying patients specific phenotypes.

For the past decade Dr. Kasirajan has been widely published and active as a presenter and lecturer. He has held key professional positions with memberships in numerous medical societies. Dr. Kasirajan was most recently Director of Clinical Research and Endovascular Therapy at East Bay Cardiovascular & Thoracic Associates in Concord, CA. Prior to that he was Associate Professor of Surgery and Director of Clinical Research at Emory University Hospital and VAMC (Division of Vascular Surgery) in Atlanta, GA.

Dr. Kasirajan completed his residency at Western Reserve Care System in Youngstown, OH and received his M.B.B.S. (Bachelor of Medicine and Bachelor of Surgery) from Madras Medical College & Government Hospital in Madras, India.

About Natural Molecular Testing Corp. (NMTC)

Natural Molecular Testing Corporation (NMTC) is a privately-owned, high-complexity molecular testing facility. NMTC provides genetic testing services and resources for our clinical partners to assist them in better caring for their patients by advancing patient care through the latest breakthroughs in genomic technology.

Link:
Natural Molecular Testing Corp. (NMTC) Names Karthikeshwar Kasirajan, M.D., as Chief Medical Officer

Ambry Genetics Reports Specific Results from Clinical Diagnostic Exome™ Testing of Patients at Kennedy Krieger Institute

February 29th, 2012

ALISO VIEJO, Calif. & BALTIMORE–(BUSINESS WIRE)–

Ambry Genetics, a global leader in genetic services with a focus on clinical diagnostics and genomics, announces specific results from one of three recent diagnoses using its proprietary new Clinical Diagnostic Exome. Four individuals with rare genetic conditions for which the cause could not previously be identified were successfully diagnosed, three at Kennedy Krieger Institute in Baltimore and one at a large, Ivy League-affiliated university hospital in New York City.

One of the cases at Kennedy Krieger Institute involves two brothers, ages 22 and 24, with profound intellectual disability and autism. The actual cause of their condition was unknown for over 20 years. Ambry Genetics Clinical Diagnostic Exome test revealed that their condition is a form of autosomal recessive intellectual disability precisely caused by mutations in the ELP2 gene. Because this gene was only recently discovered and routine testing was not available, this diagnosis would have been impossible to identify without exome sequencing.

The majority of genetic diseases are caused by mutations located in the exons, which are the regions of genes that code for protein. Exons make up about 1.5% of the genome, which in total consists of over 20,000 genes. Traditional genetic testing analyzes only one or a few specific genes at a time. In contrast, exome sequencing is a much broader test targeting the exons of nearly all genes. Ambry Genetics believes that exome sequencing will be much more useful in quickly identifying the causes of a wide range of genetic disorders that previously have gone undiagnosed.

We are the first CLIA-certified lab to offer whole exome sequencing, and moreover are the first to deliver actionable results from an exome test, as demonstrated with these results, said Charles Dunlop, chief executive officer of Ambry Genetics. However, this is just the beginning. We stand ready to solve medical mysteries for clinicians, and to bring relief to patients and their caregivers who may be suffering from conditions of unknown cause and origin. Our Clinical Diagnostic Exome test is now available to clinicians and their patients across the country, and is already covered by some national health insurance carriers. Having helped three families in these initial cases, we are eagerly anticipating helping many more.

We are most pleased to be able to share these patient-specific results from the Clinical Diagnostic Exome, said Elizabeth Chao, M.D., assistant medical director of Ambry Genetics. We are looking forward to documenting them, further, and conducting additional Clinical Diagnostic Exome tests, in coming months.

It was extremely rewarding and exciting to share these results with the families, added Julie Cohen, Sc.M., C.G.C, genetic counselor at Kennedy Krieger Institute. This is a great leap forward for clinical diagnostics and opens the door to hopefully help many clinicians find answers for the patients and caregivers who desperately need them.

About the Ambry Genetics Clinical Diagnostic Exome

Ambry Genetics is the first CLIA-certified laboratory to offer whole exome sequencing for clinical diagnostics. To date, underlying causative genes have been discovered for fewer than half of all monogenic disorders, making the Clinical Diagnostic Exome a powerful tool to help diagnose affected patients whose conditions have eluded traditional diagnostic approaches. Exome sequencing also provides a highly effective, cost- and time-saving method to diagnosis genetic diseases that are associated with multiple genes for which limited testing and/or no comprehensive panels are available. More information is available at www.ambrygen.com/clinical-diagnostic-exome.

About Ambry Genetics

Read the rest here:
Ambry Genetics Reports Specific Results from Clinical Diagnostic Exome™ Testing of Patients at Kennedy Krieger Institute

Watch: Two Sides of Integrative Medicine

February 29th, 2012

Home > Video > Health > Health News

How to Be a Bone Marrow Donor

Two Sides of Integrative Medicine

Secrets to a Successful Cleanse

‘Fighting Encephalitis’

Pricey Primping: Gold Nail Polish, Jewel Facials

Value of Selenium Supplements Questioned

Dental Care in the ER?

Mother’s Cancer Passed on to Her Baby

Fainting, Heart Health Link

Follow this link:
Watch: Two Sides of Integrative Medicine

Confused by genetic tests? NIH’s new online tool may help

February 29th, 2012

Embargoed for Release Wednesday, February 29, 2012 9 a.m. EST

An online tool launched today by the National Institutes of Health will make it easier to navigate the rapidly changing landscape of genetic tests. The free resource, called the Genetic Testing Registry (GTR), is available at http://www.ncbi.nlm.nih.gov/gtr/.

“Im delighted that NIH has created this powerful, new tool. It is a tremendous resource for all who are struggling to make sense of the complex world of genetic testing,” said NIH Director Francis S. Collins, M.D., Ph.D., who unveiled GTR at NIH’s observance of international Rare Disease Day. “This registry will help a lot of people from health care professionals looking for answers to their patients diseases to researchers seeking to identify gaps in scientific knowledge.”

Genetic tests currently exist for about 2,500 diseases, and the field continues to grow at an astonishing rate. To keep pace, GTR will be updated frequently, using data voluntarily submitted by genetic test providers. Such information will include the purpose of each genetic test and its limitations; the name and location of the test provider; whether it is a clinical or research test; what methods are used; and what is measured. GTR will contain no confidential information about people who receive genetic tests or individual test results.

Genetic tests that the Food and Drug Administration has cleared or approved as safe and effective are identified in the GTR. However, most laboratory developed tests currently do not require FDA premarket review. Genetic test providers will be solely responsible for the content and quality of the data they submit to GTR. NIH will not verify the content, but will require submitters to agree to a code of conduct that stipulates that the information they provide is accurate and updated on an annual basis. If submitters do not adhere to this code, NIH can take action, including requiring submitters to correct any inaccuracies or to remove such information from GTR.

In addition to basic facts, GTR will offer detailed information on analytic validity, which assesses how accurately and reliably the test measures the genetic target; clinical validity, which assesses how consistently and accurately the test detects or predicts the outcome of interest; and information relating to the tests clinical utility, or how likely the test is to improve patient outcomes.

“Our new registry features a versatile search interface that allows users to search by tests, conditions, genes, genetic mutations and laboratories,” said Wendy Rubinstein, M.D., Ph.D., director of GTR. “What’s more, we designed this tool to serve as a portal to other medical genetics information, with context-specific links to practice guidelines and a variety of genetic, scientific and literature resources available through the National Library of Medicine at NIH.”

GTR is built upon data pulled from the laboratory directory of GeneTests, a pioneering NIH-funded resource that will be phased out over the coming year. GTR is designed to contain more detailed information than its predecessor, as well as to encompass a much broader range of testing approaches, such as complex tests for genetic variations associated with common diseases and with differing responses to drugs. GeneReviews, which is the section of GeneTests that contains peer-reviewed, clinical descriptions of more than 500 conditions, is also now available through GTR.

The GTR database was developed by the National Center for Biotechnology Information (NCBI), part of NIHs National Library of Medicine, under the oversight of the NIH Office of the Director and with extensive input from researchers, testing labs, health care providers, patients and other stakeholders. To view video tutorials on how to use GTR, go to http://www.youtube.com/playlist?list=PL1C4A2AFF811F6F0B.

The Office of the Director, the central office at NIH, is responsible for setting policy for NIH, which includes 27 Institutes and Centers. This involves planning, managing, and coordinating the programs and activities of all NIH components. The Office of the Director also includes program offices which are responsible for stimulating specific areas of research throughout NIH. Additional information is available at http://www.nih.gov/icd/od/.

Read this article:
Confused by genetic tests? NIH’s new online tool may help

NIH Launches Genetic Testing Registry

February 29th, 2012

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) The National Institutes of Health has launched a new web resource aimed at providing consumers and healthcare providers with information about all of the genetic tests that are currently on the market.

The Genetic Testing Registry, unveiled today international Rare Disease Day was developed to serve as an encyclopedia of the genetic tests that currently exist for around 2,500 genetic diseases, one which will be updated as new tests and applications come on the market.

The goal was to create a resource that would help healthcare providers and consumers sort through information about the available tests, because most do not require premarket review by the US Food and Drug Administration.

The GTR entries will cover information on the purpose of the test, its limitations, the name and location of the providers, whether it is for clinical or research use, what methods are used, and how the results are measured. NIH will not verify the content of the entries provided by the testing providers, but it will require that they agree to a code of conduct for accuracy that will enable NIH to require submitters to correct inaccuracies or to remove such information from the resource.

On top of the basic information, the voluntary GTR will provide details about a test’s analytic validity, clinical validity, and clinical utility.

“I’m delighted that NIH has created this powerful, new tool. It is a tremendous resource for all who are struggling to make sense of the complex world of genetic testing,” NIH Director Francis Collins said in a statement.

“This registry will help a lot of people from healthcare professionals looking for answers to their patients’ diseases to researchers seeking to identify gaps in scientific knowledge.”

“Our new registry features a versatile search interface that allows users to search by tests, conditions, genes, genetic mutations, and laboratories,” said GTR Director Wendy Rubinstein. “What’s more, we designed this tool to serve as a portal to other medical genetics information, with context-specific links to practice guidelines and a variety of genetic, scientific and literature resources available through the National Library of Medicine at NIH.”

The registry was developed by the National Center for Biotechnology Information, with input from a range of stakeholders, including testing labs, healthcare providers, patients, and researchers, through a public comment period and public meetings.

See the original post here:
NIH Launches Genetic Testing Registry

New treatment using inhaled interferon may improve lung function in pulmonary fibrosis

February 29th, 2012

Public release date: 29-Feb-2012 [ | E-mail | Share ]

Contact: Cathia Falvey cfalvey@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle — Inhaled interferon-gamma may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a chronic and progressive form of lung disease caused by excessive formation of fibrotic, or scar tissue, in the lungs, according to an article published in Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp), a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com) The article on inhaled interferon-gamma (http://online.liebertpub.com/doi/abs/10.1089/jamp.2011.0919) is available free online at the Journal of Aerosol Medicine and Pulmonary Drug Delivery website.

Normally, systemic delivery of interferon-gamma can cause substantial side effects; however, delivery of aerosolized interferon-gamma directly into the lungs was shown to be safe and was associated with significantly reduced levels of profibrotic regulatory proteins. Keith Diaz, MD, Shibu Skaria, MD, Keith Harris, MD, Mario Solomita, DO, Stephanie Lau, MD, Kristy Bauer, MD, Gerald Smaldone, MD, PhD, and Rany Condos, MD, State University of New York, Stony Brook and New York University School of Medicine, NYC, show that inhalation of interferon-gamma in aerosol form three times a week for at least 80 weeks was well-tolerated by patients, with no systemic side effects.

The authors verified the presence of the drug in the material collected on lung washes and documented no change in the level of interferon-gamma in the blood during the treatment period. The report shows the results of pulmonary function tests, including forced vital capacity (FVC) and total lung capacity (TLC), and the effects of treatment on a six-minute walk test in the article entitled “Delivery and Safety of Inhaled Interferon-gamma in Idiopathic Pulmonary Fibrosis.” (http://online.liebertpub.com/doi/abs/10.1089/jamp.2011.0919)

“There is no treatment for Idiopathic Pulmonary Fibrosis, a disease usually fatal within 3-5 years,” says Gerald C. Smaldone, MD, PhD, Editor-in-Chief of the Journal and a coauthor of this article, and Professor and Chief, Division of Pulmonary and Critical Care Medicine at SUNY-Stony Brook. “The scientific community expected the injected form of interferon-gamma to help, but those studies failed. We have shown that inhaled interferon is safe with very high levels in the lungs. Now is the time to repeat the clinical trials with the inhaled form of this therapy.”

###

About the Journal

Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp) is an authoritative peer-reviewed journal published bimonthly in print and online. It is the Official Publication of the International Society for Aerosols in Medicine (www.isam.org). The Journal is the only authoritative publication delivering innovative articles on the health effects of inhaled aerosols and delivery of drugs through the pulmonary system. Topics covered include airway reactivity and asthma treatment, inhalation of particles and gases in the respiratory tract, toxic effects of inhaled agents, and aerosols as tools for studying basic physiologic phenomena. Complete tables of content and a sample issue may be viewed on the Journal of Aerosol Medicine and Pulmonary Drug Delivery (http://www.liebertpub.com/jamp) website.

About the Company

See the article here:
New treatment using inhaled interferon may improve lung function in pulmonary fibrosis

Therapy 'aiding immune disease'

February 29th, 2012

29 February 2012 Last updated at 10:39 ET

Treatment which aims to correct a rare inherited genetic defect has helped a patient at risk from serious infection, a leading hospital is reporting.

The use of gene therapy against chronic granulomatous disorder (CGD) is a third success for Great Ormond Street Hospital in London.

Patients with CGD cannot make cells to fight bacterial and fungal infection.

Scientists used a virus to deliver a functioning version of the faulty gene which causes the disease.

Clinical trials at Great Ormond Street and its linked research centre, the Institute for Child Health at University College London, have focused on rare immune conditions caused by a single gene defect.

Early trials in 16 patients with X-linked severe combined immunodeficiency syndrome (x-SCID) and Adenosine Deaminase Deficiency causing Severe Combined Immune Deficiency (ada-SCID), who previously were so vulnerable to infection they needed to live in sterile conditions, have worked well, allowing most of them to start enjoying normal lives.

The decision was taken to use a similar technique on a teenage CGD patient who had fallen prey to a serious fungal lung infection, and was not expected to survive more than a year.

One in 150,000 children has the gene defect which causes CGD, and there is only one way to cure it – with a bone marrow transplant.

In the case of the teenage patient, no matching donor was available.

Read the original:
Therapy 'aiding immune disease'

Gene Therapy Could Help Corals Survive Climate Change

February 29th, 2012

Image: Erinn Muller/Mote Marine Laboratory

Editor’s note: Climate Query is a semi-weekly feature offered by Daily Climate, presenting short Q&A’s with players large and small in the climate arena. Read others in the series at http://wwwp.dailyclimate.org/tdc-newsroom/query/climate-queries.

Kim Ritchie fell into coral research as an undergraduate, got a Ph.D. in genetics and was doing post-doctoral research in Panama when she lost her funding. With the ideal training for biotech, however, she slipped right into a startup. But when the company went bankrupt, she jumped back into research.

Today she manages the microbiology program at Mote Marine Laboratory in Sarasota, Fla., a nonprofit research center dedicated to studying marine and estuarine ecosystems. Ritchie is taking a novel approach to reviving stressed coral reefs, looking at the role bacteria can play in coral health. She is tinkering with gene therapy primarily DNA swapping to restore coral reefs by fostering beneficial bacterial growth.

Ritchie earned her doctorate in genetics from University of North Carolina, Chapel Hill, and did post-doctoral research at the Smithsonian Tropical Research Foundation in Panama. Ritchie has two grown daughters Emily and Jillian two cats and two dogs, loves watersports and enjoys cooking Mediterranean food in her spare time.

Why are reefs important? Many reasons. They are storm breaks, essentially. They’re also habitat to many commercially important species and fisheries. Coral reefs, while they make up a small percentage of the oceans, harbor a diverse assemblage of organisms.

Coral reefs face at least three threats pollution, overfishing and climate change. What has had the most impact? All three have had an effect but climate change, with its increasing temperatures and changing ocean pH, is the most detrimental because it is most closely linked with coral disease and death worldwide.

There are signs out of Australia that corals are tougher than expected. How do we know coral reefs won’t just adapt? Its not surprising and it is hopeful. There are subpopulations that dont die off. Perhaps they can reseed the coral reefs and everything becomes more resilient.

Australians are also freezing polyps and coral embryos in the hopes of recreating the Great Barrier Reef in some future era.

If the things they are saving arent resistant to whatever the change is, that might not be a good solution.

View post:
Gene Therapy Could Help Corals Survive Climate Change

Gene therapy cures life-threatening lung infection in teenage boy

February 29th, 2012

Doctors used the new technique to temporarily boost the immune system of the boy, who has an inherited condition A 16-year-old boy who was born with a life-threatening immune disorder has become the first patient to benefit from a new form of gene therapy. Doctors at Great Ormond Street Hospital in London said the treatment had only a temporary effect but was sufficient to help the boy overcome …

Continue reading here:
Gene therapy cures life-threatening lung infection in teenage boy

Sirona Biochem Announces Diabetes Preclinical Results in Chronic Study

February 29th, 2012

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Feb. 29, 2012) – Sirona Biochem Corp. (TSX VENTURE:SBM.V – News)(PINKSHEETS:SRBCF.PK – News)(FRANKFURT:ZSB.F – News), announced today its lead compound for the treatment of Type 2 diabetes significantly reduced fructosamine levels in a chronic preclinical study.

In a 28-day chronic dosing study of obese diabetic rats, Sirona Biochem’s SGLT (sodium glucose transporter) inhibitor, SBM-TFC-039, normalized diabetes and significantly lowered fructosamine levels. Fructosamine is a standard biomarker that reflects the level of glucose in the blood and that is commonly used for monitoring diabetes.

In the chronic study, SBM-TFC-039 also reduced blood glucose levels by 48% compared to the non-treated group. At the end of the study the ratio fructosamine total protein of the treated rats was reduced by 25% compared to the non-treated rats and was within 10% of the ratio for the control lean rats.

“We are very encouraged by the results we have obtained from our acute and chronic preclinical studies in the obese diabetic rat model,” said Dr. Howard Verrico, President & CEO of Sirona Biochem. “Key members of our team, including our Scientific Advisory Board, will be meeting in Vancouver this week to refine our preclinical development plan,” Dr. Verrico added.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Here is the original post:
Sirona Biochem Announces Diabetes Preclinical Results in Chronic Study

Research and Markets: Staged Diabetes Management, 3rd Edition – Based on the International Diabetes Center's Staged …

February 29th, 2012

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/6e0d7d/staged_diabetes_ma) has announced the addition of John Wiley and Sons Ltd’s new book “Staged Diabetes Management, 3rd Edition” to their offering.

This new edition of the successful Staged Diabetes Management will again address the prominent issues of primary care diabetes management based on the International Diabetes Center’s Staged Diabetes Management program, which it advocates as part of its mission statement. This systematic treatment program consists of practical solutions to the detection and treatment of diabetes, its complications, and such areas as metabolic syndrome, pre-diabete,s and diabetes in children using evidence-based medicine. The text reviews the fundamental basis of diabetes management and then addresses treatment of each type of diabetes and the major micro- and macrovascular complications.

Key Topics Covered:

Introduction.

PART ONE: DIABETES CARE FROM THE PERSPECTIVE OF STAGED DIABETES MANAGEMENT.

1 Introduction to Staged Diabetes Management.

2 Implementation of Staged Diabetes Management.

3 Characterization of Glucose Metabolism.

PART TWO: THE TREATMENT OF DIABETES.

More here:
Research and Markets: Staged Diabetes Management, 3rd Edition – Based on the International Diabetes Center's Staged …

American Diabetes Association Statement on Recent FDA Safety Changes in Labeling for Some Cholesterol-Lowering Drugs

February 29th, 2012

ALEXANDRIA, VA–(Marketwire -02/29/12)- Yesterday, the U.S. Food and Drug Administration (FDA) announced safety changes in the labeling for some cholesterol-lowering drugs (statins). According to the FDA’s safety announcement, the products include: Lipitor, Lescol, Mevacor, Altoprev, Livalo, Pravachol, Crestor and Zocor. Combination products include: Advicor, Simcor, and Vytorin.

In a statement, the FDA said, “Increases in blood sugar levels (hyperglycemia) have been reported with statin use. The FDA is also aware of studies showing that patients being treated with statins may have a small increased risk of increased blood sugar levels and of being diagnosed with type 2 diabetes mellitus.”

While there is evidence that statins can increase the risk of diabetes, the American Diabetes Association urges people with diabetes who are currently taking a statin to continue their medication unless instructed otherwise by their healthcare provider. Stopping these medications may increase the risk of diabetes-related heart attacks. “Every drug has its risks and benefits, and with statins the risk is small and can be managed,” said Vivian Fonseca, MD, President, Medicine & Science, American Diabetes Association. He adds, “On the other hand, people with diabetes, can receive great benefit from taking these medications. They’ve been proven to prevent heart attacks and prolong life.”

It is important to be aware of the risks and benefits of any medication. Patients with concerns or questions about their statin medication, or any other medication, should ask their physician, pharmacist, or other members of their health care team for more information. The American Diabetes Association continues to support the FDA in its role as the regulatory agency that makes decisions regarding drug safety and efficacy.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

Originally posted here:
American Diabetes Association Statement on Recent FDA Safety Changes in Labeling for Some Cholesterol-Lowering Drugs

Public Health Experts Address Bristol-Myers Squibb Foundation Together on Diabetes® Grantees and Applaud …

February 29th, 2012

ATLANTA–(BUSINESS WIRE)–

Public health experts from the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Public Health Service applauded grantees of the Bristol-Myers Squibb Foundation and its Together on Diabetes initiative for their collaborative efforts to improve health outcomes and reduce disparities for people living with type 2 diabetes by strengthening patients ability to manage their own care with supportive community services.

During the two-day summit at Emory University, nonprofit grantees and their partners from across the United States joined diabetes experts from the U.S. government and various academic and public health institutions to discuss how communities can build, integrate and coordinate medical, non-medical and policy efforts, and expand the base of community organizations actively bringing their know-how, reach, influence and assets to the fight against type 2 diabetes.

CDC reports that 79 million Americans are pre-diabetic and at increased risk of developing type 2 diabetes in the next 10 years. About 1.9 million new cases of diabetes are diagnosed in people age 20 and older each year. If current trends persist, as many as one in three Americans will have diabetes by 2050, CDC projects.

Nearly half of all patients who have been diagnosed with type 2 diabetes do not have their disease adequately controlled through a combination of diet, physical activity and medication. Patients with uncontrolled type 2 diabetes face increased risk of complications such as cardiovascular disease, high blood pressure and stroke; damage to the nerves, eyes and kidneys; and amputation of the fingers, toes or limbs.

While CDC has reported declining rates of some of the most serious complications of diabetes, including kidney failure, amputation of feet and legs, hospitalizations and vision loss, we are not seeing these drops in all groups, said Ann Albright, Ph.D., R.D., director of CDCs Division of Diabetes Translation, who addressed the summit Tuesday. Improving access to health care, including teaching people how to care for themselves if they have diabetes, is so important. So is strong community support for healthy lifestyles.

Together on Diabetes: Communities Uniting to Meet Americas Diabetes Challenge is the largest corporate philanthropic commitment to improving health outcomes for American adults living with type 2 diabetes. Launched in November 2010, this $100 million, 5-year initiative from the Bristol-Myers Squibb Foundation has awarded $32.57 million in grants to 17 organizations working in 23 states and the District of Columbia.

Together on Diabetes brings together some of the nations most respected and influential health care organizations and academic institutions to develop effective, comprehensive solutions that integrate public health, health care services, community supportive services and the strengths of our nations communities in order to improve health outcomes and reduce disease burden.

Rear Admiral Clara Cobb, M.S.N, R.N, an assistant U.S. Surgeon General and regional health administrator for the U.S. Public Health Services Region 4 in Atlanta, praised the Foundation and its partners for their robust efforts to improve health outcomes for American adults living with type 2 diabetes.

Together on Diabetes is apropos because the entire nation is affected by this growing chronic disease, Admiral Cobb said during Wednesdays keynote address. Communities Uniting to Meet Americas Diabetes Challenge is reflective of a collaborative and inclusive effort to penetrate and make a difference for all Americans affected directly or indirectly by diabetes.

Go here to see the original:
Public Health Experts Address Bristol-Myers Squibb Foundation Together on Diabetes® Grantees and Applaud …

Canadians Living with Diabetes Not Getting Enough Support

February 29th, 2012

LAVAL, QUEBEC–(Marketwire -02/29/12)- Editors Note: There is a backgrounder associated with this press release.

More than three million Canadians are living with diabetes(i) and yet, when it comes to managing their disease on a daily basis, more than one-in-four respondents say they feel alone.

A new 2012 survey commissioned by Sanofi Canada, being released in collaboration with the Canadian Diabetes Association, sheds light on the gaps in support for Canadians living with diabetes. Nearly 80 per cent of respondents do not have a full support system including nutrition, fitness, emotional and motivational resources to help them manage their diabetes. Sixty-three per cent feel that living with diabetes can be a burden and one-in-three wish they had someone to talk to who understands their day-to-day experiences and challenges.

“Canadians with diabetes want to be responsible and proactive when it comes to managing their disease. However, this survey reveals that they lack specific forms of needed support to manage their disease such as the opportunity to consult with experts in nutrition and physical activity as well as emotional and motivational support,” says pharmacist and certified diabetes educator Susie Jin.

Previous Canadian Diabetes Association research revealed that approximately half of Canadians living with diabetes do not have their blood glucose levels under control.

“It is not surprising that more than one-quarter (27 per cent) worry that they do not know enough about their disease in order to properly manage their blood glucose levels. Ignoring the unmet needs of Canadians with diabetes compromises their ability to self-manage their condition and can potentially lead to a perfect storm of diabetes-related complications, including heart attack, stroke, kidney failure, blindness, and depression,” adds Jin.

Support Snapshot by Province

The majority of respondents indicated low levels of diabetes support across Canada. Seventy-six per cent of respondents living in the Prairie Provinces (Alberta, Manitoba and Saskatchewan) indicated that they do not have a full diabetes support system. For Quebecers, that figure was even higher at 88 per cent.

When it comes to support and advice, almost 40 per cent of respondents report not having access to a diabetes expert such as a dietitian or nutritionist to turn to for nutrition advice and tips to meet their specific needs. Ninety per cent do not have a fitness expert to consult with when they require specific advice about how exercise impacts their diabetes. Of those who do have these supports, 63 per cent who have a diabetes nutrition expert and 64 per cent who have a fitness expert find it beneficial.

Nearly half (45 per cent) of respondents said they do not currently have emotional support in their life to help manage their disease. The survey revealed that males (57 per cent) are more likely than females (53 per cent) to have emotional support.

Go here to see the original:
Canadians Living with Diabetes Not Getting Enough Support

Stem-Cell Therapy Takes Off in Texas

February 29th, 2012

By David Cyranoski of Nature magazine

With Texas pouring millions of dollars into developing adult stem-cell treatments, doctors there are already injecting paying customers with unproven preparations, supplied by an ambitious new company.

The US Food and Drug Administration (FDA) has not approved any such stem-cell treatment for routine clinical use, although it does sanction them for patients enrolled in registered clinical trials. Some advocates of the treatments argue, however, that preparations based on a patient’s own cells should not be classed as drugs, and should not therefore fall under the FDA’s jurisdiction.

There are certainly plenty of people eager to have the treatments. Texas governor Rick Perry, for instance, has had stem-cell injections to treat a back complaint, and has supported legislation to help create banks to store patients’ harvested stem cells.

One company that has benefited from this buoyant climate is Celltex Therapeutics, which “multiplies and banks” stem cells derived from people’s abdominal fat, according to chairman and chief executive David Eller. Its facility in Sugar Land, just outside Houston, opened in December 2011 and houses the largest stem-cell bank in the United States.

Celltex was founded by Eller and Stanley Jones, the orthopaedic surgeon who performed Perry’s procedure, and it uses technology licensed from RNL Bio in Seoul. Because clinical use of adult-stem-cell treatments are illegal in South Korea, RNL has since 2006 sent more than 10,000 patients to clinics in Japan and China to receive injections.

Celltex says that although it processes and banks cells, it does not carry out stem-cell injections. It declined to answer Nature’s questions about whether its cells have been used in patients. But there is evidence that the company is involved in the clinical use of the cells on US soil, which the FDA has viewed as illegal in other cases.

Public hype

In addition to the publicity surrounding Perry’s treatment, a woman named Debbie Bertrand has been blogging about her experiences during a five-injection treatment with cells prepared at Celltex. Her blog (http://debbiebertrand.blogspot.com) hosts photographs of herself alongside Jones; Jennifer Novak, a Celltex nurse; Jeong Chan Ra, chief executive of RNL Bio; and her doctor, Jamshid Lotfi, a neurologist who works for the United Neurology clinic in Houston. Another photo is captioned: “My cells are being processed in here for my next infusion!!!” A third shows Bertrand, Lotfi and a physician called Matthew Daneshmand, who is, according to the caption, injecting Bertrand’s stem cells into an intravenous drip, ready for the infusion. Nature has been unable to contact Bertrand.

Lotfi says that he has administered cells processed by Celltex to more than 20 people. “Five or six” — including Bertrand — have multiple sclerosis and “four or five” have Parkinson’s disease, he says. Lotfi explains that patients sign up for treatment by contacting Novak, and that cells are prepared by removing about five grams of fat — containing roughly 100,000 mesenchymal stem cells — from the patient’s abdomen. Over a three-week period, the cells are cultured until they reach about 800 million cells. Lotfi says that patients get at least three injections of 200 million cells each, and that the cells do not take effect for a few months. According to Lotfi, Celltex charges US$7,000 per 200 million cells, and pays Lotfi $500 per injection.

More:
Stem-Cell Therapy Takes Off in Texas

BIOTECanada: Canadian Biotechnology Companies Championing Treatments for Rare Diseases

February 29th, 2012

OTTAWA, Ontario–(BUSINESS WIRE)–

All Canadians deserve care. BIOTECanada supports the Canadian Organization for Rare Disorders (CORD) in marking Rare Disease Day. These devastating, life-threatening and often terminal conditions affect 1 in 12 Canadians. The impact of orphan diseases on patients and families can be profound and life altering. The need to access safe and effective treatments is often urgent and overwhelming.

BIOTECanada congratulates CORD in their work on behalf of the 3.2 million Canadians with one of 7,000 rare diseases, commented Peter Brenders, President and CEO, BIOTECanada. We are recommending the federal government finally recognize Canada needs a national Orphan Product Policy to set a standard of equality for Canadians with rare and life-threatening conditions. Regulatory changes must be introduced to define a rare disease, and provide the conditions for biotechnology companies to bring their research to market.

While over 35 Canadian companies have had orphan products approved in the US, in Canada, the Common Drug Review has issued do not list recommendations (to the provinces) for over 75% of rare disease therapeutics approved by Health Canada.

“We invest in developing novel drug therapies for these rare medical conditions precisely because the need is so great. Our commitment to patients with rare diseases goes beyond innovation, to working with the medical community and governments to ensure that all those in need have access to these crucial therapies, commented Kevin Leshuk, Vice President & General Manager Celgene Inc. But Canadians have been waiting far too long for governments to catch up to the policies that have existed around the world and consequently, some Canadians are left behind.

Biotechnology therapeutics offer new hope in treating rare disorders for Canadians. Due to the genetic nature of these conditions, scientists can identify specific variations in genes or cells linked to a condition. These biomarkers can be used to identify people with a particular disease, or those at risk of developing a disease. This insight helps guide the development of treatments.

Read the original post:
BIOTECanada: Canadian Biotechnology Companies Championing Treatments for Rare Diseases

Commercialization of Advanced Biofuels to be Key Theme at BIO World Congress on Industrial Biotechnology and …

February 29th, 2012

WASHINGTON–(BUSINESS WIRE)–

Biofuel and biobased product company executives, scientists and government officials from across the globe will speak in breakout sessions at BIOs 9th annual World Congress on Industrial Biotechnology and Bioprocessing. The worlds largest industrial biotechnology conference for business leaders, investors, academics and policymakers in biofuels, biobased products, renewable chemicals, synthetic biology, food ingredients and biomass comes to Orlando, April 29 – May 2 at the Gaylord Palms Resort & Convention Center.

Continued commercialization of the industrial biotechnology sector can drive the creation of a biobased economy, which can strengthen the nations economic security and enhance energy security. Breakout sessions examining the future outlook and keys to commercialization of biofuels and specialty chemicals include:

Biomass Saccharification Enzymes Reaching Cost Targets to Enable Commercial Biorefineries Build-up for Advanced Biofuels Production Monday, April 30, 8:30am 10am

Advanced Biofuels: Keys to Commercialization Monday, April 30, 10:30am 12pm

The Future of Aviation Biofuels Monday, April 30, 2:30pm 4pm

Syngas-based Fuels and Chemicals Gain Industrial Relevance Wednesday, May 2, 10:30am 12pm

Speakers at the World Congress will highlight the keys to commercialization in industrial biotechnology, said Brent Erickson, executive vice president of BIOs Industrial & Environmental Section. Whileindustrial biotechnology offers a clear value proposition, a number of hurdles need to be addressed to fully realize the commercial potential of biobased products and chemicals. Fortunately, we seem to be on the path to commercialize these solutions and to build a worldwide biobased economy, which is good news for business, consumers and our environment.

BIOs World Congress will feature six breakout session tracks over three days, with industry presentations on Advanced Biofuel Technologies; Algae and Feedstock Crops; Renewable Chemical Platforms and Biobased Materials; Specialty Chemicals; Synthetic Biology and Metabolic Engineering; and Technical Presentations. The full program of breakout panel sessions and speakers is available online.

Online pre-registration for reporters and editors is now open. All programs at the BIO World Congress on Industrial Biotechnology and Bioprocessing are open to attendance by members of the media. Complimentary media registration is available to editors and reporters with valid press credentials working full time for print, broadcast or web publications.

Follow this link:
Commercialization of Advanced Biofuels to be Key Theme at BIO World Congress on Industrial Biotechnology and …

Plandai Biotechnology, Inc. Announces Appointment of Additional Renowned Scientist to Its Scientific Board

February 29th, 2012

SEATTLE, WA–(Marketwire -02/29/12)- Planda Biotechnology, Inc. (OTC.BB: PLPL.OB – News) Chief Executive Officer, Roger Duffield, announced today that Dr. Ming Hu, Professor of Pharmaceutics at the University of Houston, has accepted a position on the company’s scientific board. Dr. Hu has published more than 76 peer reviewed journal articles and 13 review articles and book chapters, and is widely considered a leading expert in the field of drug metabolism and natural dietary chemicals. His book titled “Oral Bioavailability” was published in 2011 by Wiley and Sons.

With Dr. Christina Nance from the Baylor School of Medicine, Dr. Hu is the co-investigator in a US government-funded clinical trial NCT01433289, to determine the safety, dosing and antiviral effects of epigallocatechin gallate (EGCG) in capsule form with HIV-1 infected, clinically stable individuals that are not on concomitant antiretroviral (ARV) Therapy.

Dr. Hu has extensively studied the absorption of chemicals in the upper intestines, as a process for effectively delivering flavonoid nutrients, such as those found in green tea extract; and has proposed a method of understanding the coupling between conjugating enzyme and efflux transporters. Conjugating enzymes are traditionally recognized as one of the major biological barriers to the entry of xenobiotics (drugs) into systemic circulation. Drugs that undergo extensive conjugation generally have poor bioavailability properties. Dr. Hu has also pioneered the concept of using lipozyme as a powerful, fat-digesting complex that aids digestion and enhances absorption of nutrients.

Dr. Hu’s extensive published research extends to improving the bioavailability of natural, organic compounds with cancer fighting properties including both phenolics and ginseng; purifying anticancer ingredients of herbal materials and decreasing the bioavailability of dietary carcinogens.

Roger Duffield, Chief Executive Officer of Planda, commented, “In his role on Planda’s scientific board, Dr. Hu will be able to apply his specific expertise to the development of highly effective, bioavailable products that are easily metabolized in the body. Having a researcher of his caliber and background on our team is a huge benefit as we continue building Planda into a leader in the field of biotechnology.”

About Planda Biotechnology, Inc.

Planda Biotechnology, Inc., through its recent acquisition of Global Energy Solutions, Ltd. and its subsidiaries, focuses on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry. Its principle holdings consist of land, farms and infrastructure in South Africa.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Planda’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Planda is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Go here to read the rest:
Plandai Biotechnology, Inc. Announces Appointment of Additional Renowned Scientist to Its Scientific Board

Adult stem cell coatings for regenerative medicine – Review article

February 29th, 2012

close select a state: Please choose Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming

Current state : Not selected.

See original here:
Adult stem cell coatings for regenerative medicine – Review article







Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Web Design by PlatinumShore.com & Web Hosting by TradeWebHosting.com